Transparency Market Research
Thin Client Market Expected to Hit USD 2.1 billion, Achieving a 4.2 % CAGR by 2031– Analysis by Transparency Market Research, Inc.
January 29, 2024 04:07 ET | Transparency Market Research
Wilmington, Delaware, United States, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global thin client market was projected to attain US$ 1.4 billion in 2022. It is...
84bd90f5-4a1f-42a8-8eb1-5cb062a0b6ac.png
FemTech Market Projected to Exceed USD 127.1 Billion by 2033, Driven by the increasing focus on women's health
January 29, 2024 04:06 ET | Market.Us
New York, Jan. 29, 2024 (GLOBE NEWSWIRE) -- According to Market.us, the Global FemTech Market size is projected to surpass around USD 127.1 Billion by 2033, and it is poised to reach a CAGR of 7.9%...
22157.jpg
Advanced Semiconductor Packaging Report 2024-2035, Featuring Review of Drivers Drivers ML/AI, Data Centers & EV/ADAS & Emerging Approaches of System-In-Package, Monolithic 3D ICs & Advanced Substrates
January 29, 2024 04:02 ET | Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Global Market for Advanced Semiconductor Packaging 2024-2035" report has been added to ResearchAndMarkets.com's offering. The global landscape of...
22157.jpg
Global EV Battery Enclosures Market Set for Substantial Growth: Trends and Opportunities 2023-2028
January 29, 2024 04:01 ET | Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Global EV Battery Enclosures Market Size, Share, Trend, Forecast, Competitive Analysis, and Growth Opportunity: 2023-2028" report has been added to ...
Alvotech Announces P
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
January 29, 2024 04:00 ET | Alvotech
The study, which assessed the pharmacokinetics, safety, and tolerability of AVT03 compared to Prolia® in healthy adult subjects, met its primary endpoints Prolia® and Xgeva® (denosumab) are indicated...
BGG Logo.jpg
BNTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioNTech SE Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
January 29, 2024 04:00 ET | Bronstein, Gewirtz & Grossman, LLC
NEW YORK, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been...
Orion Corporation an
Orion Corporation and Newel Health enter into licensing agreement for a digital therapeutic (DTx) ODD-403 (“Rohkea”) in pain
January 29, 2024 04:00 ET | Orion Oyj
ORION CORPORATION PRESS RELEASE 29 JANUARY 2024 at 11.00 EET          Orion Corporation and Newel Health enter into licensing agreement for a digital therapeutic (DTx) ODD-403 (“Rohkea”) in pain ...
sphericalinsightsoptionblue.png
Global Polymethyl Methacrylate Market Size To Worth USD 8.5 Billion By 2032 | CAGR Of 6.3%
January 29, 2024 04:00 ET | SPHERICAL INSIGHTS LLP
New York, United States , Jan. 29, 2024 (GLOBE NEWSWIRE) -- The Global Polymethyl Methacrylate Market Size to Grow from USD 5.2 Billion in 2022 to USD 8.5 Billion by 2032, at a Compound Annual...
BGG Logo.jpg
ASRT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Assertio Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
January 29, 2024 04:00 ET | Bronstein, Gewirtz & Grossman, LLC
NEW YORK, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been...
Alvotech Announces P
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
January 29, 2024 04:00 ET | Alvotech
 The study, which assessed the pharmacokinetics, safety, and tolerability of AVT03 compared to Prolia® in healthy adult subjects, met its primary endpointsProlia® and Xgeva® (denosumab) are indicated...